Tang Capital reports 0% stake in KalVista Pharma
KalVista Pharmaceuticals, Inc. received an updated Schedule 13G/A (Amendment No. 5) from Tang Capital entities and Kevin Tang regarding ownership of KalVista common stock (CUSIP 483497103).
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
KalVista Pharmaceuticals, Inc. received an updated Schedule 13G/A (Amendment No. 5) from Tang Capital entities and Kevin Tang regarding ownership of KalVista common stock (CUSIP 483497103).
The filing states that Tang Capital Management, LLC, Kevin Tang, Tang Capital Partners, LP, Tang Capital Partners International, LP, Tang Capital Partners III, Inc., and Tang Capital Partners IV, Inc. each beneficially own 0 shares of KalVista common stock, representing 0% of the class. The filing also reports 0 shares for sole or shared voting power and for sole or shared dispositive power, and confirms that these reporting persons now hold ownership of 5 percent or less of this class of securities.
Key Figures
Key Terms
beneficially owned financial
sole voting power financial
Schedule 13G/A regulatory
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What does the latest Schedule 13G/A for KALV disclose about Tang Capital's ownership?
What percentage of KalVista (KALV) does Tang Capital now beneficially own?
Which entities are included in the Tang Capital Schedule 13G/A for KALV?
What voting power in KalVista (KALV) stock does Tang Capital report?
What class of KalVista (KALV) securities is covered in this Tang Capital filing?
AI-generated analysis. How Rhea-AI works. Not financial advice.